A recent review highlights the evolving landscape of senotherapeutics, focusing on novel strategies to target senescent cells that accumulate with age. These cells contribute to chronic inflammation and degenerative aging, prompting significant interest in therapies that can either clear or modulate their effects. Current approaches include senostatics, senolytics, and senomorphics, with the latter two showing promise in early clinical trials, yet facing challenges such as limited efficacy and safety concerns.

The review emphasizes a shift towards precision senotherapy, which aims to address the limitations of first-generation senolytic agents. Emerging strategies include immune-based senolysis, tissue-precision proteolysis-targeting chimeras (PROTACs), and microbiome-epigenetic modulation. These innovative approaches seek to enhance the specificity and effectiveness of treatments while minimizing systemic toxicity, though they also introduce new complexities and safety considerations.

For longevity professionals, this synthesis underscores the potential of precision therapies in combating age-related disorders. I encourage you to delve deeper into the full review to explore these promising developments in senotherapeutics.

Source: fightaging.org